adMare has helped build more than 25 life sciences companies across the country that have attracted more than $1.4B of investment, employ more than 900 Canadians, and have a combined worth of over $3B.
Click on the logo to find more information on our portfolio companies.
Abdera Therapeutics Inc. is a precision oncology company focused on developing next-generation effective targeted alpha radiation therapies (TATs) for patients with relapsed, refractory and metastatic cancers. For more information visit: www.abderatherapeutics.com.
Bellus Health is developing BLU-5937, a P2X3 antagonist, to help people with chronic cough and other afferent hypersensitization-related disorders. For more information visit: www.bellushealth.com.
Bright Angel Therapeutics is a pre-clinical stage biotechnology company focused on the development of novel therapeutics for the treatment of drug-resistant and life-threatening fungal infections. For more information visit: www.brightangeltherapeutics.com.
Encycle Therapeutics was created to develop a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. The company was acquired by Zealand Pharma in 2019. For more information: www.encycletherapeutics.com.
Epigene Therapeutics was established to advance novel, orally bioavailable epigenetic modulators for the targeted treatment of cancer.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. For more information visit: www.eupraxiapharma.com.
Find Therapeutics is a discovery and development company dedicated to the development of the next generation of GPCR allosteric modulators to treat rare diseases. For more information visit: www.findtherapeutics.com.
Flosonics Medical is a medical device company focused on developing non-invasive sensors to improve the management of critically-ill patients. For more information visit: www.flosonicsmedical.com.
FORUS Therapeutics is a biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer. For more information visit: www.forustherapeutics.com.
ImStar Therapeutics is a private biotechnology company developing new therapeutic approaches to treat patients with neurodegenerative diseases. For more information visit: www.imstartx.com.
Inversago Pharma is a clinical-stage, biotech company aiming to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information visit: www.inversago.com.
Jenthera Therapeutics is offers a new CRISPR technology by directly addressing the inherent limitations of current CRISPR methodologies. For more information visit: www.jenthera.com.
Kairos Therapeutics was a biopharmaceutical company that developed a proprietary next-generation antibody-drug conjugate platform. It was merged with Zymeworks in 2016.
KalGene is a biotechnology company developing precision medicine therapeutics designed to slow the progression of Alzheimer’s disease with an antibody-based approach. For more information visit: www.kalgene.com.
KisoJi is a privately-held next-generation antibody company developing multi-specific antibodies to improve outcomes in oncology. For more information visit: www.kisojibiotech.com.
Mesentech is a pre-clinical platform company developing innovative drugs that rebuild bone lost to disease and trauma. For more information visit: www.mesentech.com.
Neurasic Therapeutics is a company created to advance research that aims to provide new opiate-sparing pain-relieving drugs. For more information visit: www.neurasictherapeutics.com.
Nexelis is an immunology-centric CRO specialized in preclinical models and clinical assay development in single and multiplex formats and sample analysis for low-, mid- and large-scale clinical testing. For more information visit: www.nexelis.com.
NIMIUM Therapeutics is a Montreal biotech focused on the development of an innovative therapeutic to treat cardiometabolic diseases. For more information visit www.nimium.ca.
Precision Nanosystems Inc. creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases. For more information visit: www.precisionnanosystems.com.
Sepset Biosciences is a diagnostic company developing a point-of-care blood test for hospitals to identify septic patients in the emergency room (ER), and predict those who will have high risk for organ failure. For more information visit: www.sepset.ca.
Sitka Biopharma is a preclinical biotechnology company focused on developing its breakthrough nanoparticle platform technology to increase absorption of drugs in difficult-to-penetrate tissues. For more information visit: www.sitkabiopharma.com.
SoundBite Medicalis a medical devices company developing and commercializing proprietary wire-based devices and generator technology that delivers shockwave energy within the cardiovascular system to treat chronic total occlusions (CTO’s). For more information visit: www.soundbitemedical.com.
viDA Therapeutics is advancing first-in-class drugs for the treatment of autoimmune and age-related chronic inflammatory diseases. For more information visit: www.vidatherapeutics.com.
Zucara Therapeutics Inc. is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. For more information visit: www.zucara.ca.
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. For more information visit: www.zymeworks.com.